FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SHERWIN STEPHEN A						2. Issuer Name and Ticker or Trading Symbol BIOSANTE PHARMACEUTICALS INC BPAX								Relationship eck all appli X Directo	cable)	g Pers	on(s) to Issu 10% Ow	
(Last) (First) (Middle) C/O BIOSANTE PHARMACEUTICALS, INC. 111 BARCLAY BOULEVBARD					03/	3. Date of Earliest Transaction (Month/Day/Year) 03/30/2012								below)			Other (s below)	
(Street) LINCOLNSHIRE MN 60069 (City) (State) (Zip)					_	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable le) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(5																	
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)						ction 2A. Deemed Execution Date,			3. Transac Code (II 8)	ction	4. Securities Acquired (AD Disposed Of (D) (Instr. 3.5)		ed (A) or str. 3, 4 and	5. Amou Securitie Benefici Owned F Reporter Transact	5. Amount of Securities FC Beneficially (D Owned Following Reported Transaction(s) (Instr. 3 and 4)		: Direct · Indirect I str. 4)	7. Nature of Indirect Beneficial Dwnership Instr. 4)
Common	Stock	-				Securities Acquired, Disposed of, or Beneficially Owned calls, warrants, options, convertible securities)									D			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of		6. Date Exercisal Expiration Date (Month/Day/Year)		of Securities Of Securities Underlying Derivative Se (Instr. 3 and		d Amount ies g	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)		Date Exercisable		xpiration ate	Title	or Number of Shares					
Non- Statutory Stock Option (right to	\$0.68	03/30/2012			A		25,000		03/30/2013	3 0	3/29/2022	Common Stock	25,000	\$0	25,000	0	D	

Explanation of Responses:

/s/ Phillip B. Donenberg, attorney-in-fact

** Signature of Reporting Person Date

03/30/2012

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.